Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Analyst consensus and Net cash floor.
ACCE opinionTScan Therapeutics Inc. Common Stock (TCRX)
Fair value
Not available
ACCE price target
$0.13
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $0.20 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
23
out of 100
Analysts
20% buy
5 covering
1-year return
-91.3%
Dividend yield
0.00%
TScan Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
TScan Therapeutics develops T-cell therapies built on its TCRdb platform, which uses single-cell sequencing to identify T-cell receptors for cancer targets and has moved into clinical trials for hematologic malignancies. The attraction is a platform that has generated a pipeline of candidates, but the commercial case is a long way off. Revenue fell 65.8% and operating margin sits near -2,901%, so the business is funded entirely by its balance sheet, not by sales or earnings. At a $16M market cap, the equity is priced as a cash-burning option on trial readouts, and the score of 23/100 with no index membership reflects that the next data points will decide whether it is worth a deeper look.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
severe
Going concern risk
Free cash flow is -$139.7M against a $15M market cap, and revenue fell 65.8% YoY. Cash burn this large relative to the equity value raises serious solvency questions.
high
Revenue collapse and deep losses
Revenue is down 65.8% YoY and 61.7% QoQ, with an operating margin of -2901.3% and ROE of -95.8%. The business is shrinking while losses are enormous.
high
Trades above ACCE target
The price of $0.20 sits 53.8% above the ACCE price target of $0.13, which was last updated 2026-10-14. The market is pricing in more than our model supports.
AI research notes
AI-assisted·How I use AIWritten Oct 23, 2026 · figures from 2026-10-23 · prices to Oct 23, 2026
Why it could do well
Analysts' mean price target is $1.00, which is 354.5% above the current share price of $0.20.
Revenue grew at an average of 56.9% per year over five years, showing the business has expanded substantially over time.
TScan beat earnings expectations last quarter, with EPS of -0.23 against -0.29 expected, a surprise of 20.7%.
Why it could disappoint
Free cash flow over the last twelve months was -$140M, a heavy cash burn set against a market value that is far smaller.
Revenue fell 65.8% year over year, so recent sales are moving sharply the wrong way.
Only 20% of analysts rate the stock Buy or Strong Buy, with just 1 of 5 positive.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 11, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where TCRX's valuation models land
Price
$0.20
Model fair valueConfidence: low
about $0.60
Model
Fair value
Upside
Analyst consensus
Net cash floor
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores